See more : Mon Courtier Energie Groupe S.A. (ALMCE.PA) Income Statement Analysis – Financial Results
Complete financial analysis of Accelerate Diagnostics, Inc. (0H8E.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Accelerate Diagnostics, Inc., a leading company in the Medical – Specialties industry within the Healthcare sector.
- Paramount Global (PARAP) Income Statement Analysis – Financial Results
- Hi Gold Ocean No.3 Ship Investment Company (153360.KS) Income Statement Analysis – Financial Results
- Anhui Jinhe Industrial Co.,Ltd. (002597.SZ) Income Statement Analysis – Financial Results
- Orion Minerals Limited (ORN.AX) Income Statement Analysis – Financial Results
- Fujimori Kogyo Co., Ltd. (7917.T) Income Statement Analysis – Financial Results
Accelerate Diagnostics, Inc. (0H8E.L)
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.06M | 12.75M | 11.78M | 11.17M | 9.30M | 5.67M | 4.18M | 246.00K | 147.00K | 122.00K | 48.00K | 43.20K |
| Cost of Revenue | 9.51M | 9.45M | 12.16M | 6.71M | 4.90M | 5.19M | 2.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 2.55M | 3.30M | -381.00K | 4.46M | 4.40M | 483.00K | 1.77M | 246.00K | 147.00K | 122.00K | 48.00K | 43.20K |
| Gross Profit Ratio | 21.15% | 25.90% | -3.23% | 39.94% | 47.33% | 8.52% | 42.47% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 25.35M | 26.92M | 21.94M | 21.26M | 25.35M | 26.84M | 21.20M | 29.40M | 26.02M | 20.27M | 10.82M | 4.30M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 31.23M | 39.19M | 49.24M | 46.90M | 51.89M | 54.01M | 44.43M | 36.20M | 17.88M | 10.70M | 4.31M | 3.04M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -331.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 56.58M | 66.11M | 71.18M | 68.16M | 77.23M | 80.85M | 65.96M | 65.60M | 43.90M | 31.11M | 15.36M | 8.21M |
| Cost & Expenses | 66.09M | 75.56M | 83.34M | 74.87M | 82.13M | 86.04M | 68.36M | 67.95M | 45.70M | 31.11M | 15.36M | 8.21M |
| Interest Income | 1.12M | 551.00K | 88.00K | 855.00K | 2.81M | 7.27M | 908.00K | 494.00K | 70.00K | 57.00K | 29.00K | 4.80K |
| Interest Expense | 7.74M | 3.77M | 15.55M | 15.55M | 14.26M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.25M | 3.00M | 2.52M | 3.00M | 2.60M | 2.56M | 2.20M | 2.35M | 1.79M | 888.00K | 363.00K | 103.20K |
| EBITDA | -50.77M | -59.81M | -69.04M | -60.30M | -70.23M | -77.81M | -61.99M | -64.15M | -43.76M | -30.10M | -14.94M | -7.26M |
| EBITDA Ratio | -421.05% | -468.99% | -586.00% | -543.69% | -755.39% | -1,372.28% | -1,484.03% | -26,565.04% | -29,766.67% | -24,671.31% | -31,118.75% | -16,811.11% |
| Operating Income | -54.03M | -62.81M | -71.56M | -63.70M | -72.83M | -80.37M | -64.18M | -67.70M | -45.55M | -30.99M | -15.30M | -7.37M |
| Operating Income Ratio | -448.03% | -492.51% | -607.37% | -570.53% | -783.38% | -1,417.44% | -1,536.61% | -27,520.73% | -30,985.71% | -25,399.18% | -31,875.00% | -17,050.00% |
| Total Other Income/Expenses | -6.74M | 235.00K | -6.10M | -14.50M | -11.59M | -7.75M | 649.00K | 394.00K | 51.00K | 57.00K | 18.00K | -794.40K |
| Income Before Tax | -60.77M | -62.57M | -77.66M | -78.20M | -84.42M | -88.12M | -63.54M | -67.31M | -45.50M | -30.93M | -15.28M | -8.16M |
| Income Before Tax Ratio | -503.92% | -490.67% | -659.12% | -700.43% | -907.99% | -1,554.06% | -1,521.07% | -27,360.57% | -30,951.02% | -25,354.92% | -31,837.50% | -18,888.89% |
| Income Tax Expense | 850.00K | -77.00K | 45.00K | 5.00K | -111.00K | 211.00K | 493.00K | -933.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -61.62M | -62.49M | -77.70M | -78.21M | -84.31M | -88.33M | -64.03M | -66.37M | -45.50M | -30.93M | -15.28M | -8.16M |
| Net Income Ratio | -510.97% | -490.06% | -659.50% | -700.47% | -906.80% | -1,557.78% | -1,532.87% | -26,981.30% | -30,951.02% | -25,354.92% | -31,837.50% | -18,888.89% |
| EPS | -4.94 | -7.61 | -12.59 | -13.96 | -15.47 | -16.21 | -11.84 | -12.94 | -10.11 | -7.09 | -4.06 | -3.22 |
| EPS Diluted | -4.94 | -7.61 | -12.59 | -13.96 | -15.47 | -16.21 | -11.84 | -12.94 | -10.11 | -7.09 | -4.06 | -3.22 |
| Weighted Avg Shares Out | 12.48M | 8.22M | 6.17M | 5.60M | 5.45M | 5.45M | 5.41M | 5.13M | 4.50M | 4.36M | 3.76M | 2.54M |
| Weighted Avg Shares Out (Dil) | 12.48M | 8.22M | 6.17M | 5.60M | 5.45M | 5.45M | 5.41M | 5.13M | 4.50M | 4.36M | 3.76M | 2.54M |
Source: https://incomestatements.info
Category: Stock Reports